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INVESTIGATING THE DEFECTS OF POSTNATAL GLOBAL FLI1 DELETION  




Scleroderma (SSc) is an autoimmune disease characterized by dysfunctional immunity, 
vasculopathy, and fibrosis of the skin and internal organs. There is a poor prognosis for 
SSc patients and effective therapeutics have not yet been developed. Many mouse models 
have been developed, but most fail to recapitulate all of the symptoms seen in SSc 
patients. In this study we characterize a Fli1flox/flox mouse with CAG Cre under the beta-
actin promoter.  Based on what has been previously described in mice with deletion of 
Fli1 in specific cell types, we predicted that global postnatal deletion of Fli1 will result in 
systemic fibrosis, vasculopathy, and inflammation in these mice.  The penetrance of a 
phenotype was highly variable; however, mice that developed a phenotype displayed 
disorganized vascular networks, fibrosis and proinflammatory cytokines and chemokines 
in the skin and lungs after 4 and 8 weeks of Fli1 deficiency.  Increased macrophage and 
dendritic cell populations were observed in the lungs after 8 weeks.  Fli1flox/flox CAG Cre 
mice exhibited hair loss after 5 months of Fli1 deletion.  Since our experiments focus 
mainly on the lungs and skin, more experiments are required to characterize these mice to 
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 Systemic sclerosis (SSc), or Scleroderma, is a multi-organ autoimmune connective tissue 
disease with high morbidity and mortality, for which there are no effective therapies [1]. 
Hallmarks of SSc include immune dysfunction, vasculopathy, and excessive fibrosis of 
the skin and internal organs, and it most commonly effects women in their forties and 
fifties [1,2]. Patients are classified as either limited (lcSSc) or diffuse (dcSSc) based on 
the extent of cutaneous involvement; while helpful to predict disease progression and 
potential clinical complications, this classification is far from ideal [1,3].  Even though 
both groups seem to have distinct disease manifestations, there are SSc patients that 
cannot be characterized by this dichotomous categorization [3]. Amongst the most 
serious complications, interstitial lung disease (ILD), and pulmonary hypertension (PAH) 
are the leading cause of death in SSc [1]. Recent studies also implicate cardiomyopathy 
with myocardial fibrosis and diastolic dysfunction as a poor predictor of survival [1,4].  
Environmental factors are likely to be involved in the initiating event and disease 
progression, likely acting on a permissive genetic background [2].  
SSc Etiology and Pathogenesis 
The etiology of SSc is unknown, however, early insult to microvasculature promotes 
sustained innate and adaptive immune involvement, subsequent inflammation, and 
exacerbated fibrosis [5].  The sensitivity of endothelial cells makes them susceptible to 
various injurious stimuli, which could result in EC activation, apoptosis, or endothelial to 
mesenchymal transition (EndoMT); EndoMT is the change in phenotype from an 
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endothelial to mesenchymal cell [2]. EndoMT has been implicated in the pathogenesis of 
SSc due to the observation of this transformation occurring in pulmonary and dermal 
vessels in SSc patients [6]. Stromal progenitors, FBs, ECs, pericytes and dermal 
adipocytes have the ability to transform into an alpha-smooth-muscle (α-SMA) 
expressing, collagen-producing cell type, contributing to the pathogenesis of SSc [1,2].  
Raynaud phenomenon is the initial clinical manifestation of SSc, supporting the 
involvement of the vascular compartment early in disease pathogenesis [2].  Immune 
dysregulation also plays an important role, with both innate and adaptive immunity being 
involved [2].  These alterations ultimately lead to persistent fibroblast activation and 






Figure 1: SSc Pathogenesis A) The triad underlying the clinical manifestations of SSc 
[1]. B) Injury to endothelial cells can result in several mechanisms including apoptosis, 




Transcription Factor Fli1 
Friend leukemia integration 1 (Fli1) is expressed in endothelial cells, immune cells, 
keratinocytes and fibroblasts [7].  As part of the E-twenty six (ETs) family of 
transcription factors that have a conserved DNA binding domain, Fli1 binds a core 5’-
GGAA/T-3’ consensus sequence [8]. The transcriptional activity of Fli1, whether 
activation or suppression, is influenced by the carboxy-terminal transcriptional activation 
(CTA) domain [9]. Fli1 is expressed early on in vascular endothelium and hematopoietic 
stem cells, where it serves crucial roles [7]. During embryogenesis, ETs variant 2 (Etv2) 
binds to the promoter region of Fli1 and activates its expression along with other genes 
responsible for vasculogenesis. The Fli1 protein is able to sustain its gene expression by 
binding to its own promoter region for continued support of vascular integrity [10]. Mice 
with homozygous Fli1 gene die during embryogenesis due to disrupted vasculature [2]. 
Data from our laboratory demonstrates a role for Fli1 in maintaining vascular 
homeostasis [11].  Aberrant Fli1 expression is seen in several autoimmune diseases and 
likely contributes to their pathogenesis [12]. In vitro studies reveal that epigenetic 
modifications to the Fli1 gene in fibroblasts also control cellular events preceding the 
fibrotic phenotype via enhanced promoter methylation in SSc fibroblasts [13]. Fli1 






Figure 2: Fli1 in mouse embryogenesis  
Timing and control of Fli1 in mouse 
embryogenesis. Fli1 regulates vascular 
morphogenesis and integrity early on in mouse 
development [10].  
 
Fli1 and SSc Fibrosis 
ETs transcription factors have been identified as contributors of extracellular matrix 
(ECM) remodeling; in particular, Fli1 was found to suppress type I collagen expression in 
human dermal FBs by several mechanisms [2, 15]. Type I collagen is the most abundant 
component of the ECM, and SSc patients exhibit exaggerated deposition of collagen in 
the skin and internal organs [16]. Transformation growth factor (TGF)-β signaling is a 
major contributor to SSc fibrosis, by controlling the transcriptional activity through a 




Figure 3: TGF-β signaling on Fli1 
TGF-β signaling causes PKC-δ 
translocation to the nucleus where it 
phosphorylates Fli1; subsequent 
acetylation of Fli1 by PCAF results 
in Fli1 dissociation from DNA and 





TGF-β isoforms are secreted by various cells types and stimulate migration, reactive 
oxygen species formation, collagen secretion and trans-differentiation [2]. Fibroblasts are 
tissue-resident mesenchymal cells that synthesize and can degrade ECM; in SSc, 
activated fibroblasts overproduce ECM macromolecules, being influenced by cell-cell 
contact, hypoxia, reactive oxygen species, signaling mediators, and changes occurring 
within the ECM [2].  The decrease in collagen degradation paired with the increase in 
activated fibroblasts and cells undergoing EndoMT leads to pathogenic fibrotic 
manifestations [2]. In previous studies, reduction of Fli1 in mouse dermal fibroblasts 
resulted in increased connective tissue growth factor (CTGF), type I collagen production 
and reduction of matrix metalloproteinases [9].  
Fli1 and SSc Vasculopathy 
SSc vasculopathy can be described as progressive structural damage of capillaries leading 
to reduced capillary density and blood flow [2].  ECs are highly responsive to stimuli and 
play an important role in regulating blood flow and immune responses by modulating 
expression of adhesion molecules and genes responsible for vascular permeability; they 
secrete proinflammatory cytokines and chemokines in response to injury [4]. Fli1 is 
markedly decreased in the ECs of SSc patients, and due to the importance of Fli1 in 
maintaining vascular homeostasis by regulation expression of EC cell markers like VE-
cadherin and platelet endothelial cell adhesion molecule (PECAM)-1, we expect that the 
depletion of Fli1 is mainly responsible for the development of vascular abnormalities 
[11].  Mice with conditional deletion of Fli1 in endothelial cells show a disorganized, 
fragile vascular networks, and decreased expression of VE-cadherin and PECAM-1, 
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similar to those seen in SSc patients [5,11].  It was also found in SSc ECs, neuropilin-1, a 
co-receptor of vascular endothelial growth factor receptor (VEGFR)-2 that is 
transcriptionally controlled by Fli1, was decreased contributing to an anti-angiogenic 
program [2]. 
Fli1 and SSc Autoimmunity 
Chronic inflammation typically results in fibrosis [1]. Innate immune responses in SSc 
involve damage associated molecular patterns (DAMPs) interaction with pattern 
recognition receptors (PRRs), activation of macrophages, mast cells and dendritic cells. 
The adaptive immune response helps to sustain chronic inflammation [1]. Th2 and Th17 
T-cell subsets predominate in early stages of disease, which in turn contributes to the 
activation of macrophages to a profibrotic phenotype, secreting interleukin (IL)-10 and 
TGF-β [19]. In SSc biopsies, macrophages expressing profibrotic markers were found in 
perivascular regions as well as between thickened collagen bundles [20]. Fli1 was found 
to regulate development of immune cells of myeloid lineage in mice; by functionally 
deleting the CTA domain from Fli1 in a mouse model; increased populations of 
monocytes, macrophages and dendritic cells were seen in the bone marrow, spleen, and 
peripheral blood [21]. A recent study found that monocytes isolated from SSc patients 
showed decreased Fli1 levels when compared with healthy controls. In vitro studies, in 
which conditioned media from macrophages with depleted Fli1 was used in culture with 
human dermal fibroblasts, showed increased type I collagen expression, confirming the 




Current Limitations in SSc Research 
There are many animal models of SSc, but they fail to reflect the genetic component of 
the disease [22]. Transgenic models have not been able to capture the fibrotic, immune, 
and vascular aspects of this disease in a single setting, and the use of exogenous 
substances, like bleomycin, are commonly used to induce a phenotype [22]. 
Existing models of SSc have led to the development of therapies, but the clinical efficacy 
remains highly variable, as the in vivo models do not sufficiently replicate the disease 
[2,22].  Pathophysiological aspects of SSc can be simulated in different models of the 
disease 
 
Figure 4: Classification of mouse models of SSc. Table indicating the involvement of 
fibrosis, vasculopathy, and inflammation in existing mouse models of SSc; organized by 
spontaneous genetic models, inducible models, transgenic models and knockout models 
[modified from 23] 
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The Fos-related antigen-2 (FRA-2) transgenic mouse model develops many of the 
features of SSc [23].  Fra-2 is overexpressed in the skin and lungs of SSc patients, and 
mice with overexpression of Fra-2 develop fibrosis in the skin and lungs, as well as 
microangiopathy and immune involvement [22,23].  EC apoptosis precedes the vascular 
phenotype in these mice and the expression of Fra-2 is independent of TGF-β [23], 
suggesting that although the phenotype seems representative of SSc, mechanistically, it 
may not represent all of the contributors to disease pathogenesis.  
Fli1flox/flox CAG Cre Mice  
Due to the involvement of Fli1 in immune cell development, FB and EC homeostasis, we 
propose a mouse model, in which we utilize the global postnatal deletion of Fli1.  We 
utilized a tamoxifen inducible Cre-recombination system driven by the beta actin 
promoter coupled with the cytomegalovirus early enhancer to delete floxed exon 3 of 
Fli1.  Cre recombinase under the control of the beta actin promoter ensures the 
widespread deletion of functional Fli1 in cells and tissues.  In this study, we aim to 
characterize these mice to determine if they can serve as a novel transgenic mouse model 









Transgenic Mouse Generation  
All experimental procedures were conducted in accordance with the guidelines of the 
National Institute of Health and were approved by the Boston University Animal Care 
and Use Committee.  A Fli1 targeting vector purchased from the KOMP Repository was 
used to generate floxed Fli1 mice. 129 Agouti embryonic stem cells with the inserted 
KOMP vector were generated at the Transgenic Mouse Core at Harvard Medical School 
(Boston, MA) and used for blastocyst injection to generate chimeric mice, which were 
then selected for germline transmission. Heterozygous mice harboring the targeted gene 
mutation were crossed with transgenic C57BL/6J mice expressing FLP1 recombinase 
(Flpe) in all tissues, under the β-actin promoter (transgenic B6.Cg-Tg(ACTFlpe) 
9205Dym/J, available from the Jackson Laboratory, USA, Stock number 005703). The 
Fli1flox/flox mice were crossed to C57BL/6 mice for 8 generations. Mice expressing Cre 
recombinase under the chicken β-actin promoter coupled with the cytomegalovirus 
(B6.Cg-Tg9CAG-cre/Esr1*)5Amc/J) immediate-early enhancer were purchased from the 
Jackson Laboratory (Bar Harbor, ME) (Stock number 004682) and crossed with 
Fli1flox/flox mice. Tamoxifen-inducible Cre-mediated recombination in these mice results 
in the deletion of Fli1 in widespread cells and tissues. Heterozygous CAGCre males with 
Fli1flox/flox were bred with females with Fli1flox/flox to produce viable experimental 






Genomic DNA was isolated from 2mm tail biopsies from 21-day old mice. Biopsies were 
incubated overnight at 55 °C in DNA digestion buffer (50 mM Tris-HCL pH 8.0, 100 
mM EDTA pH 8.0, 100 mM NaCl, 1 % SDS) with a final concentration of proteinase K 
at 0.5 mg/mL. Neutralized phenol/chloroform/iso-amyl alcohol (25:24:1) was added and 
mixed for one hour at room temperature. After carefully separation of the aqueous phase, 
DNA was precipitated using 100 % ethanol. DNA was washed in 70 % ethanol and 
resuspended in 1X TE buffer (1 M Tris pH 8.0, 0.5 M EDTA pH 8.0).  
Fli1loxP CAGCre (ERt2) Genotyping  
PCRs were performed with ~200 ng of genomic DNA, 1X PCR buffer, 3.0 mM Mg2+ 
(Bioline), 300 uM dNTPs (New England Biolabs, Ipswich, MA), 1.5 U ChoiceTaq Blue 
DNA Polymerase (Thomas Scientific), 100 uM primer Fli1-3loxPF5 (5’-
GACTCAAACCAGGGAAAGTTGC-3’), 100 uM primer Fli1-3loxPR5 (5’-
TTGGGAAGGTGGAATCTAGCAG-3’). 100 uM primer Fli1loxP-2nd5F (5’-
ACCTTTGCTCCACACATCTGA-3’) and 100 uM primer Fli1loxP-2nd5R (5’-
ACCTTGGTTACAGGACTGAGTG-3’) were used in a separate reaction to confirm the 
presence of both loxP sites flanking exon 3 of Fli1. Reactions were incubated at 94 °C for 
3 min, then cycled 40 times (94 °C for 30 sec, 12 °C for 1 min, 72 °C for 1 min) followed 
by a 2 min extension at 72 °C. Reactions were separated on a 2 % agarose gel and 
visualized with ethidium bromide. 100 uM primer CAGCreF (5’-
AGGCAGCTCACAAAGGAACAAT-3’), 100 uM primer CAGCreR (5’-
TCGTTGCATCGACCGGTAA-3’), 100 uM primer CAGCtrlF (5’- 
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CTAGGCCACAGAATTGAAAGATCT-3’), and 100 uM primer CAGCtrlR (5’-
GTAGGTGGAAATTCTAGCATCATCC-3’) were used in one PCR reaction. 
Heterozygous mice produced a 300 bp transgene product and a 324 bp internal positive 
control, while wild type mice produced a 324 bp internal positive control product.  
Tamoxifen Administration 
Tamoxifen (Sigma-Aldrich, St. Louis, MO) was dissolved in sterile corn oil at a 
concentration of 20 mg/ml by shaking overnight at 37 °C and then stored protected from 
light at 4 °C. Injection doses were determined by weight, mice 4 – 6 weeks of age 
received intraperitoneal (IP) injections 75 mg/kg body weight or 100 mg/kg body once 
every 24 hours for 5 consecutive days. Mice were euthanized for organ harvest 10 days, 4 
weeks, 8 weeks and 5 months days following the last injection.   
Vascular Permeability 
Mice were intravenously administered sterile 0.5 % Evans Blue (EB) in 1X PBS through 
a lateral tail vein injection. 30 min following injection, mice were euthanized with CO2 
and cervical dislocation. Skin was photographed to evaluate vascular permeability.  
Gene Expression Analysis (RT-qPCR) 
Tissue was stored in RNAlater (Invitrogen, Carlsbad, CA) solution at -80 °C until RNA 
isolation. Total tissue RNA was isolated using the RNeasy Fibrous Tissue Mini Kit 
(Qiagen, Hilden, Germany). 1 ug was reverse transcribed with random hexamers and the 
Transcriptor First Strand cDNA synthesis kit (Roche Applied Science, Penzberg, 
Germany) according to the manufacturer’s protocol. Real-time PCR was performed using 
the StepOnePlus Real-Time PCR system (Applied Biosystems, Foster City, CA). The 10 
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ul amplification mixture contained 1 ul of complementary DNA, 0.5 mM of each primer, 
and 5 ul of SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA). The 2-
ΔΔCT method was used to evaluate relative changes in the levels of genes of interest. 
Primers are listed in Table 1. 
Western Blot 
For western blot, whole tissue was subjected to mechanical disruption using the Tissue 
Lyser II (Qiagen, Hilden, Germany) in a lysis buffer containing 150 mM NaCl, 1 % 
Triton X-100, 50 mM Tris-HCl pH 8.0, 0.5 % sodium deoxycholate, 0.1% sodium 
dodecyl sulfate, and proteinase inhibitor cocktail (Roche Applied Science, Penzberg, 
Germany). Protein extracts were subjected to SDS-PAGE and transferred to 
nitrocellulose membranes. Membranes were incubated overnight at 4 °C with primary 
antibodies, washed in TBS containing 0.01% Tween 20, TBS-T) and incubated with the 
appropriate horse-radish peroxidase-conjugated secondary antibody for 1 hour at room 
temperature. After washing in TBS-T, visualization was performed by using enhanced 
chemiluminescence (ECL; Pierce, Waltham, MA). The following antibodies were used: 
anti-Fli1 (Abcam), at a dilution of 1:1000, and a control mouse β-actin (Sigma, St. Louis, 
MO) was used at a 1:5000 dilution.  
Trichrome Stain 
Tissue were deparaffinized and hydrated using HistoClear (National Diagnostics, Atlanta, 
GA) clearing agent and a graded alcohol series. Staining for 4 week and 8 weeks samples 
was done using a kit (Thermo Scientific, Waltham, MA) according to the manufacturer’s 
protocol. Briefly, sections were incubated in Bouin’s solution at 60 °C for one hour. 
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Washed in water. Incubated in working hematoxylin solution for 10 minutes. Washed in 
water. Stained in trichrome stain for 15 minutes. Washed in water, dehydrated in ethanol 
and cleared before mounting.  Slides were imaged using the Olympus FlouView FV10i 
confocal microscope (Olympus, Waltham, MA).  For 5 month skin sections, trichrome 
stain was performed by iHISTO (Woburn, MA) and viewed using CaseViewer2.3. 
Hematoxylin and Eosin Stain 
Tissue were deparaffinized and hydrated using HistoClear (National Diagnostics, Atlanta, 
GA) clearing agent and a graded alcohol series. Slides were incubated in Gill’s 
Hematoxylin for 2 minutes, washed twice in water, and incubated in 0.3% ammonia 
hydroxide for 1 minute. Sections were washed in water and incubated in 75% ethanol, 
followed by 95% ethanol for 2 minutes each. Incubation in Eosin Y solution lasted for 30 
seconds before dehydrating, clearing, and mounting.  Slides were imaged using the 
Olympus FlouView FV10i confocal microscope (Olympus, Waltham, MA).  For 5 month 
skin sections, trichrome stain was performed by iHISTO (Woburn, MA) and viewed 
using CaseViewer2.3. 
Picrosirius Red Stain 
Tissue were deparaffinized and hydrated using HistoClear (National Diagnostics, Atlanta, 
GA) clearing agent and a graded alcohol series. Fixation was achieved with incubation in 
Bouins’ solution (Fisher, Hampton, NH) at 55 °C for 1 hr. A 10 min incubation in 0.1 % 
Fast green (Fisher F-99) is followed by a 1 % acetic acid wash. Sections were washed in 
water and incubated in 0.1% Sirius red (Sigma 0-0303) for 30min. Tissue sections were 
dehydrated in an ethanol series and cleared in HistoClear before mounting. Slides were 
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imaged using the Olympus FlouView FV10i confocal microscope (Olympus, Waltham, 
MA).  
Immunohistochemistry  
Immunohistochemistry was performed on 4 % paraformaldehyde/PBS, paraffin-
embedded lung tissues sections using a VectastainABC kit. Sections 5 uM thick were 
mounted on APES (aminopropyltriethoxy silane solution)-coated slides, deparaffinized 
with HistoClear (National Diagnostics, Atlanta, GA) and hydrated in a graded ethanol 
series. Antigen retrieval was performed using 1 mM Tris-EDTA pH 9.0. Endogenous 
peroxidase was blocked by hydrogen peroxide. Sections were blocked in normal horse 
serum.  Sections were incubated overnight at 4 °C with antibodies against CD45 at a 
dilution of 1:200. Secondary ImmPRESS IgG polymer (Vector) was used for a 
subsequent 30 min incubation. Immunoreactivity was visualized with diaminobenzidine 
(Vector Laboratories, Burlingame, CA), and sections were counterstained with 
hematoxylin. Images were collected using an Olympus (BH-2) microscope.  
Immunofluorescence 
Immunofluorescence was performed on 4 % paraformaldehyde/PBS, paraffin-embedded 
lung tissues sections. Sections 5 uM thick were mounted on APES (aminopropyltriethoxy 
silane solution)-coated slides, deparaffinized with HistoClear (National Diagnostics, 
Atlanta, GA) and hydrated in a graded ethanol series. Antigen retrieval was performed 
using 1 mM Tris-EDTA pH 9.0. Endogenous peroxidase was blocked by hydrogen 
peroxide. Sections were then blocke in BLOXALL (Vector Laboratories, Burlingame, 
CA), followed by 2.5% normal horse serum.  Goat anti-mouse Col1 (Southern Biotech, 
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Birmingham, AL), was used at a dilution of 1:2000.  Appropriate Vector HRP-
ImmPRESS Polymers (goat) were used to detect primary antibodies, following 
fluorescent CF dye tyramide conjugates for tyramide signal amplification (Biotium, 
Fremont, CA): CF594 tyramide. Quenching was achieved using hyfrogen peroxide. 
Coverslips were mounted with Vectashield with DAPI (Vector Laboratories, Burlingame, 
CA) and slides were imaged using the Olympus FlouView FV10i confocal microscope 
(Olympus, Waltham, MA).  
Lung Dissociation for Flow Cytometry 
Before harvesting, lungs were perfused through the right ventricle to remove 
erythrocytes. Following harvest, the left lobes of the lungs were washed in 1X PBS and 
dissociated using the MACs Lung Dissociation Kit (Miltenyi Biotec 130-095-927, 
Gladbach, Germany) according to the manufacturer’s protocol. Briefly, the lung was 
mechanically disrupted using the gentleMACS dissociator and incubated in a buffer-
enzyme mix at 37 °C for 30 min. Following a secondary mechanical disruption with the 
gentleMACS dissociator, samples were filtered and subjected to ACK lysis buffer 
(Gibco) to remove remaining erythrocytes. Samples were washed twice in 1X PBS 
containing 2 % FBS, and resuspended in 1X PBS. 
FACs Analysis 
Cells were counted and stained with directly conjugated monoclonal anti-mouse 
antibodies against CD8, CD4, CD11b, CD11c, B220, and F4/80. All stains were 
performed with isotype controls. Flow cytometry was performed on the LSRII cytometer 
(BD), and data were analyzed from 250,000 gated events using FlowJo.  
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Subsection One (such as Statistical Analyses) 
Prism 8 (GraphPad) was used for all statistical analysis. Data analysis was done using a 






















Table 1. Mouse qPCR Primers 
Gene 
Name 
Forward Primer Reverse Primer 
⍺SMA CCCACCCAGAGTGGAGAA ACATAGCTGGAGCAGCGTCT 
𝛽-actin CTAAGGCCAACCGTGAAAAG ACCAGAGGCATACAGGGACA 
CCL2 CATCCACGTGTTGGCTCA GATCATCTTGCTGGTGAATGAGT 
CCL7 TTCTGTGCCTGCTGCTCATA TTGACATAGCAGCATGTGGAT 
CTGF CTGCAGACTGGAGAAGCAGA GATGCACTTTTTGCCCTTCTT 
CD163 TCTCAGTGCCTCTGCTGTCA CGCCAGTCTCAGTTCCTTCT 
Col1⍺1 GCCAAGAAGACATCCCTGAAG TGTGGCAGATACAGATCAAGC 






CX3CL1 CGCGTTCTTCCATTTGTGTA CATGATTTCGCATTTCGTCA 
CXCL1 AGACTCCAGCCACACTCCAA TGACAGCGCAGCTCATTG 
CXCL10 TCTCACTGGCCCGTCATC GCTGCCGTCATTTTCTGC 




HIF1⍺ GAGCAACTACCTGTTCACCAAA GGGATTTCTCCTTCCTCAGC 




IFN𝛽 CTGGCTTCCATCATGAACAA AGAGGGCTGTGGTGGAGAA 






IL10 CAGAGCCACATGCTCCTAGA TGTCCAGCTGGTCCTTTGTT 
MMP12 TGATGCTGTCACAACAGTGG GTAATGTTGGTGGCTGGACTC 
MMP9 ACGACATAGACGGCATCCA GCTGTGGTTCAGTTGTGGTG 
MX1 GGGTAGCCACTGGACAGACT GGCTCTCACAGCTTCTTGCT 
PDGFR⍺ GGAGGAGACAGATGTGAGGTG GGAGGAGAACAAAGACCGCA 
PDGFR𝛽 TTGCAACGAGAAAGCCGGA CTATCTACCCACTCGCTCGC 
TGF𝛽1 TGGAGCAACATGTGGAACTC CAGCAGCCGGTTACCAAG 
TGF𝛽2 TGGAGTTCAGACACTCAACACA AAGCTTCGGGATTTATGGTGT 









Generation of Fli1flox/flox CAG Cre Mice 
Our goal was to generate a viable and fertile transgenic mouse model that, upon 
controlled induction, resulted in the global deletion of Fli1.  Mice expressing Cre 
recombinase under the chicken β-actin promoter coupled with the cytomegalovirus 
immediate-early enhancer were purchased from the Jackson Laboratory.  When the CAG 
Cre mice are bred with mice containing loxP-flanked sequences, in this case exon 3 of 
Fli1, inducible Cre-mediated recombination results in the deletion of functional Fli1 in 
widespread cells and tissues.  Several crosses were needed to generate experimental mice 
(figure 5B); first, homozygous floxed Fli1 mice were bred with a mouse heterozygous for 
the CAG Cre transgene.   
 
Figure 5: Fli1loxP/loxP CAG Cre Mouse Generation Breeding scheme to generate floxed 
Fli1 mice (modified from Jackson Laboratories)(left panel); genotyping results for CAG 
Cre and Fli1flox/flox,labels indicate band meaning 
 
19 
Mice heterozygous for a floxed Fli1 allele and heterozygous for the CAG Cre 
transgene were bred with mice that were homozygous for floxed Fli1.  Approximately 
25% of the progeny from this cross resulted in mice homozygous for floxed Fli1 and 
heterozygous for CAG Cre.  Mice with this genotype were considered experimental mice; 
mice homozygous for CAG Cre are not viable or fertile.  Genotypes for floxed Fli1 and 
CAG Cre were confirmed by southern blot (figure 5).  4 weeks and 8 weeks after the final 
tamoxifen injection, mice were euthanized and Fli1 protein and mRNA expression were 
evaluated in different tissues to ensure efficient deletion of Fli1. 
 
Figure 6: Fli1 Expression Fli1 protein expression (left panel) and relative mRNA 
expression from whole tissue extracts from the heart, lung, and skin 10 days after Cre 
induction. Fli1 relative mRNA expression (right panel) from whole tissue extracts from 
the lung and skin 4 weeks and 8 weeks after Cre induction All data shown as mean ±SD. 
Non-parametric Mann-Whitney test was used for statistical analysis. *P<0.05, **P<0.01 
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In a preliminary experiment, CAG Cre showed the most Fli1 loss in the lung and 
heart tissue, with both the protein and gene expression of Fli1 being reduced in 
experimental mice.  In a subsequent experiment, Fli1 deletion was evaluated 4 and 8 
weeks after the tamoxifen injection series (figure 6). Fli1 gene expression was decreased 
at both 4 and 8 weeks in both the skin and lungs following Cre induction; however, 
depletion of Fli1 protein expression in these tissues could not be confirmed in all mice, 
which contributed to much of the variability seen within groups.  
Vasculopathy in Fli1flox/flox CAG Cre Mice 
To determine whether the postnatal loss of Fli1 in endothelial cells promotes 
fragile vascular networks, an assay was performed using Evans Blue. After 10 days 
(figure 7) and 4 weeks (data not shown), mice with global Fli1 deletion showed in 
increase in vascular permeability (figure 7B) when compared to wild type littermate 





Figure 7: Vessel Permeability with 
Evans Blue (A) Fli1flox/flox mice with no 
Cre transgene (WT) 10 days after Cre 
induction (B) Fli1flox.flox mice with the 






Fibrosis in Fli1flox/flox CAG Cre Mice 
To determine if postnatal global loss of Fli1 led to fibrosis in the skin of our 
experimental mice, a trichrome stain was performed to evaluate collagen architecture and 
deposition in the dermis (figure 8).  
 
Figure 8: Trichrome and Skin Upper panel represents the structure of normal healthy 
skin. Lower panel shows trichrome stain in mouse skin [Madhero 88 and M.Komorniczak 
– CC-BY-3.0] (A) Mouse 2, wild-type skin 4 weeks after Cre induction (B) Mouse 1 
Fli1flox/flox CAG Cre skin 4 weeks after Cre induction (C) Mouse 6, Fli1flox/flox CAG Cre 
skin 4 weeks after Cre induction (D) Mouse 8, wild-type skin 8 weeks after Cre induction 
(E) Mouse 9, Fli1flox/flox CAG Cre skin 8 weeks after Cre induction  4x (F) Mouse 11, 
Fli1flox/flox CAG Cre skin 8 weeks after Cre induction  4x 
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Wild-type mice had a preserved dermal adipose layer 4 weeks (figure 8A) and 8 weeks 
(figure 8D) after Cre induction.  In the experimental group, mice 1, 3, and 6 had the 
greatest Fli1 deletion in the skin after 4 weeks; however, although there were similar 
levels of Fli1 deletion in this group mouse 1 exhibited a loss of the dermal adipose layer 
and thickening of the dermis (figure 8B), while mouse 6 developed densely packed 
collagen bundles (figure 8C).  After 8 weeks, experimental mice 9, and 11 had the most 
Fli1 deletion at the mRNA level; mouse 9 showed some thickening of the epidermis 
(figure 8E) while some collagen deposition within the dermal adipose tissue was 
observed in mouse 11 (figure 8F), indicating that activated fibroblasts may be present, or 
EndoMT could be occurring within the dermis. 50% of mice developed evidence of 
fibrosis in the skin.  
 Real-time PCRs were performed to determine how Fli1 deficiency affects 
profibrotic gene expression in the skin (figure 9). There were no significant changes in 
profibrotic gene expression in the skin after 4 or 8 weeks. Matrix metalloproteinase 
expression was unchanged in the skin of experimental mice compared to controls; 
however, TIMP1 was increased at both 4 weeks and 8 weeks after Cre induction, 
supporting the deposition of ECM by inhibiting metalloproteinases in the skin.  CD163 
was increased 4 weeks and 8 weeks, suggesting the presence of profibrotic macrophages 
[19].  There was a slight increase in TGF-β3 and Col5⍺1, but no significant or striking 
changes in other profibrotic gene expression in the skin when compared to wild-type 
controls.  Interestingly, several mice showed increased expression of PDGFR⍺ and 




Figure 9: Profibrotic gene expression in the Skin After 4 weeks and 8 weeks, loss of 
Fli1 in widespread cells and tissues modulates expression of profibrotic genes in the skin. 
Relative mRNA expression was determined by quantitative RT-PCR. n=1 independent 
experiment. All data shown as mean ±SD. Non-parametric Mann-Whitney test was used 
for statistical analysis. *P<0.05, **P<0.01  
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patients [2].   HIF1β, was also increased after 4 weeks in experimental mice suggesting 
signs of hypoxia due to vessel rarefaction in the skin.  Relative mRNA expression of 
profibrotic genes may need to be evaluated before there is histological evidence of 
fibrosis to detect changes in relative mRNA expression between groups. 
To determine if a fibrotic phenotype was limited to the skin, a trichrome stain was 
performed in the lungs (figure 10).  Compared to wild-type controls, experimental mice 
had collagen deposition in perivascular regions surrounding larger bronchi and smaller 
vessels 4 weeks after Fli1 deletion. 50 % of mice developed fibrosis in bronchovascular 
units. Mouse 6 developed fibrosis in the skin (figure 8C) and in the lungs (figure 10D) 
after 4 weeks. Mouse 5 had comparable levels of Fli1 expression, but only developed 
collagen deposition around small vessels in the lung (figure 10C), while the skin was 
unaffected.  After 8 weeks, the lungs of experimental mice resembled the wild type 
control mice (data not shown) with no evidence of collagen deposition. 
 
Figure 10: Trichrome in the Lung (A) Mouse 2, wild-type lung 4 weeks after 
tamoxifen injections. (B) Mouse 3, Fli1flox/flox CAG Cre lung 4 weeks after Cre induction 
(C) Mouse 5, Fli1flox/flox CAG Cre lung 4 weeks after Cre induction (D) Mouse 6, 
Fli1flox/flox CAG Cre lung 4 weeks after Cre induction 4X 
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Profibrotic gene expression was evaluated in the lungs (figure 11).  MMP12 was 
significantly increased after 4 weeks and continued to be elevated in mice after 8 weeks. 
Figure 11: Profibrotic gene expression in the Lung After 4 weeks and 8 weeks, loss of 
Fli1 in widespread cells and tissues modulates expression of some profibrotic genes in 
the skin. Relative mRNA expression was determined by quantitative RT-PCR. n=2 
independent experiments. All data shown as mean ±SD. Non-parametric Mann-Whitney 
test was used for 8 week statistical analysis; unpaired t-test was used for 4 week analysis. 
*P<0.05, **P<0.01  
TIMP1, Col1α1, and Col3α1 were increased after 4 weeks in experimental mice, 
providing more evidence of a profibrotic program in the lungs after 4 weeks.  CD163, 
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although not significant trended toward increase after 4 weeks, suggesting the presence of 
profibrotic macrophages in the lungs.  After 8 weeks, several mice showed elevated 
MMP12 and TIMP1 expression, indicating sustained activation of mechanisms 
responsible for sustained ECM remodeling even though fibrosis was not observed in the 
lungs after 8 weeks in a trichrome stain (data not shown).   
To determine if fibrosis developed in the heart of our mice, we performed a 
picrosirius red stain in the heart 4 weeks after Cre induction (figure 12).  There was no 
pathologic collagen deposition in the hearts of experimental mice when compared to 
wild-type controls. These mice do not develop fibrosis in the heart after 4 weeks of Fli1 
deficiency.  The heart was not evaluated after 8 weeks, but heart involvement would be 
expected in later stages of disease.  Experimental mice may require a prolonged 
pathologic phenotype and additional injury before there is heart involvement. 
 
 
Figure 12: Picrosirius Red 
Stain in the Heart A and B) 
Wild-type heart 4 weeks after 
tamoxifen injections. B and 
C) Fli1flox/flox CAG Cre heart 





Immune dysregulation in Fli1flox/flox CAG Cre Mice 
To evaluate immune dysfunction in the lungs, a hematoxylin and eosin (H&E) stain was 
performed. After 4 weeks of Fli1 downregulation, experimental mice exhibited marked 
infiltration or proliferation of cells within the alveoli when compared to wild type 
controls (figure 13).  Mouse 6 had the most exacerbated phenotype, exhibiting signs of 
alveolar hemorrhage and aberrant proliferation (figure 13 C).  After 8 weeks, some 
experimental mice had a decrease in alveolar space, but most mice were comparable to 
wild-type controls, suggesting there may be a protective restorative mechanism following 
pulmonary injury in these mice.   
 
Figure 13: H&E Stain (A) Mouse 2, wild-type lung 4 weeks after tamoxifen injections 
(B) Mouse 3,  Fli1flox/flox CAG Cre lung 4 weeks after Cre induction (C) Mouse 6, 
Fli1flox/flox CAG Cre lung 4 weeks after Cre induction (D) Mouse 8, wild-type lung 8 
weeks after tamoxifen injections (E) Mouse 9, Fli1flox/flox CAG Cre lung 8 weeks after 
Cre induction  (F) Mouse 7, Fli1flox/flox CAG Cre lung 8 weeks after Cre induction. 20x  
 
An immunohistochemical stain using anti-CD45 was done to evaluate leukocyte 
infiltration to the lung; mouse 5 and 6 had increased leukocyte infiltration (figure 14); 
however, this was not observed in all experimental mice, and was not statistically 




Figure 14: IHC anti-CD45 Lung A) Mouse 2, wild-type lung 4 weeks after tamoxifen 
injections 4X and 20X. (B) Mouse 5, Fli1flox/flox CAG Cre lung 4 weeks after Cre 
induction (C) Mouse 6, Fli1flox/flox CAG Cre lung 4 weeks after Cre induction 4X and 
20x; red boxes indicate region of 20X image 
 
Flow cytometry was performed to compare immune cell populations in 
experimental and control mice 8 weeks after Fli1 deletion. In the H&E stain, 
experimental mice after 8 weeks seemed to have a healthy phenotype in the lungs (figure 
13 E-F), but FACs analysis showed experimental mice had increased dendritic cell and 
macrophage populations, and a decreased B-cell population when compared to wild-type 
mice (figure 15).  These changes may be attributed to loss of Fli1; however, these 
changes may not be pathologic, but could explain the lack of a profibrotic phenotype 8 
weeks after Cre induction.  It is interesting that innate antigen presenting cells were 
increased while adaptive B-cells decreased; however, the B220 epitope that was utilized 
to identify B-cells in lung cell populations may not be truly representative of that group.  





Figure 15: Immune cell populations in the lung Gating strategy for FACs analysis; 
lymphocyte population, doublets, live/dead, macrophages, dendritic cells, B-cells, CD4+ 
T-cells and CD8+ T-cells (upper panel); quantification of the cell population by 
percentage based on 250,000 events. All data shown as mean ±SD. Non-parametric 
Mann-Whitney test was used for statistical analysis. *P<0.05, **P<0.01 
 
 
The expression of proinflammatory genes was evaluated in the lungs. The 
expression of CCL2, TNF⍺ and IFNβ were increased in the lung after 4 weeks, but not 8 
weeks (figure 16) suggesting infiltration of monocytes, induction of EndoMT, and 
provides insight into the inflammatory response, respectively, in early stages. CXCL10 
was the markedly increased after 4 weeks and 8 weeks in the lung suggesting a more 





Figure 16: Proinflammatory gene expression in the lung Loss of Fli1 increases 
inflammatory gene expression after 4 weeks and 8 weeks in the lung. Relative mRNA 
expression was determined by quantitative RT-PCR. n=2 independent experiments. All 
data shown as mean ±SD. Non-parametric Mann-Whitney test was used for 8 week 
statistical analysis; unpaired t-test was used for 4 week analysis. *P<0.05, **P<0.01  
 
other immune cell types to the lung.  IFNβ was not significantly increased, but MX1 
expression was significantly increased after 4 weeks and continued to be elevated in 
experimental mice after 8 weeks. In conjunction with increased expression of IL10, 
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IFI44, CXCL1, CXCL10, and TNFα, this could indicate a type I interferon response [25].  
IL-1β expression was increased after 8 weeks, which could mean that activation of the 
inflammasome pathway also contributes the inflammatory phenotype in these mice.  
 
 
Figure 17: Proinflammatory gene expression in the skin  Loss of Fli1 modulates 
inflammatory genes expression in the skin. Relative mRNA expression was determined 
by quantitative RT-PCR. n=1 independent experiment. All data shown as mean ±SD. 
Non-parametric Mann-Whitney test was used for statistical analysis. *P<0.05, **P<0.01 
 
In contrast to the lung, CXCL10 was reduced in the skin both 4 weeks and 8 
weeks after Fli1 reduction (figure 17); CXCL10 is increased in the serum and skin of SSc 
patients [26].  CCL7 was increased after 8 weeks suggesting the presence of activated 
profibrotic macrophages in the skin.  There was much variability within groups; however, 
mice that developed fibrosis in the skin also had higher levels of proinflammatory gene 
expression.  Interestingly, IFNβ was reduced after 4 weeks and 8 weeks, while MX1 was 
increased after 8 weeks.  For gene expression statistical analysis in the skin, 2 mice were 
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used in the wild-type control groups, while 4 mice were used in experimental groups.  
For gene expression statistical analysis in the lung, 5 mice were used in the 4 week 
control group, 7 mice were used in the 4 week experimental group, 2 mice were used in 
the 8 week control group, and 4 mice were used in the 8 week experimental group.  
After 5 months of Fli1 deletion, mice developed a visible phenotype in the skin 
(figure 18).  Experimental mice had increased hair loss when compared to wild-type 
controls.  Wild-type mice also displayed hair loss suggesting that this is part of the aging 
process in these mice, but the loss of Fli1 in keratinocytes could be contributing to the 
phenotype observed in experimental mice. Fli1-deficient keratinocytes have been 
identified in SSc, and in vivo models have shown that loss of Fli1 in these cells 
contributes to dermal and esophageal fibrosis [27].  
 
 
Figure 18: Hair Loss wild-type mice (left panel) and Fli1flox/flox CAG Cre (right panel) 5 






 A trichrome stain was done to compare experimental mice to control mice (figure 
19).  Areas of hair loss (affected skin) and unaffected skin of experimental mice were 
used to determine if a fibrotic phenotype persists in the skin after 5 months of Fli1 
deletion, and if such a phenotype is limited to areas of hair loss.  There was no evidence 
of fibrosis in these mice; however, affected skin (figure 19D,E) had a decreased number 
of hair follicles.  This pattern of hair loss may be consistent with Alopecia.  
 
Figure 19: Trichrome in Skin After 5 Months A) Mouse 14 wild-type skin (B) Mouse 
15, unaffected Fli1flox/flox CAG Cre skin (C) Mouse 16, unaffected Fli1flox/flox CAG Cre 
skin (D) Mouse 15, affected Fli1flox/flox CAG Cre skin (E) Mouse 16, affected Fli1flox/flox 
CAG Cre skin. 4X magnification 
 
 To assess skin for inflammatory involvement, an H&E stain was done in skin 5 
months after Fli1 deletion (figure 20).  There were no significant differences between 
experimental and control mice, and the typical Alopecia “swarm of bees” pattern of 
lymphocyte infiltrates [28] surrounding hair follicles was not observed.  Inflammation in 
Alopecia typically occurs during acute stages of the disease and can resolve over time.  In 
later stages of disease, hair loss and accumulation of melanin in the upper dermis can be 
observed [28].  Although mice seem to develop some irregular pigmentation (figure 18), 
more experiments are required to definitively characterize the mechanisms behind the 
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late stage phenotype observed in the skin of experimental mice.  The control group also 
developed some hair loss and pigmentation incontinence, suggesting Fli1 may not be the 
culprit, but may exacerbate skin involvement over time.  
 
Figure 20: H&E in Skin After 5 Months A) Mouse 14 wild-type skin (B) Mouse 15, 
unaffected Fli1flox/flox CAG Cre skin (C) Mouse 16, unaffected Fli1flox/flox CAG Cre skin 
(D) Mouse 15, affected Fli1flox/flox CAG Cre skin (E) Mouse 16, affected Fli1flox/flox CAG 






 Despite the effort committed to elucidating the mechanisms of SSc, effective 
treatments have not yet been developed. The animal models used to research SSc are not 
able to capture this complex multi-system disease in one setting, resulting in incomplete 
characterization of the disease and therapeutics.  Here we show a new mouse model that, 
despite having 50% penetrance of a fibrotic phenotype in our experiments, has the 
potential to develop many of the systemic effects seen in SSc patients.  
All experimental mice developed a vascular phenotype, confirming the effects of 
Fli1 depletion on endothelial cell injury and the contribution to vascular damage [11].  
Endothelial Fli1 serves an essential role in regulating vascular homeostasis including 
suppression of proinflammatory genes [11]; however, although we observed 
vasculopathy in the skin of all mice the proinflammatory phenotype was mainly localized 
in the lungs.  An increase in proinflammatory cytokines after 4 weeks and 8 weeks may 
be evidence of an acute and sustained inflammatory reaction, as there was no difference 
between wild-type and experimental mice in the H&E stain in the lung after 8 weeks.  
Flow cytometry showed increased macrophage and dendritic cell populations in the lung 
after 8 weeks, which could contribute circulating TGFβ [2].   
Fli1 haploinsufficiency in a bleomycin-induced skin fibrosis model increased 
proportions of Th2-like T-regulatory cells, which promote profibrotic macrophage 
differentiation [29].  In the lungs, but not the skin, CXCL10 gene expression was 
strikingly increased, possibly contributing to modulation of adhesion molecules and 
monocyte stimulation, in conjunction with increased CD163 gene expression, confirms a 
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profibrotic phenotype [20].  CD163 positive cells can be found in both the peripheral 
blood and in collagen bundles in the skin of SSc patients [20].  Increased gene expression 
of MX1 and IFI44 suggests a type I interferon induced response. Interferon-β (IFNβ) 
expression was not increased when Fli1 was depleted, but we did not evaluate interferon-
α (IFNα), which has been associated with autoimmune disease by increased levels in the 
sera of patients with systemic lupus erythematosus (SLE) [25].  A mouse model with 
targeted MMP12 deletion resulted in a reduction of Fas-induced pulmonary fibrosis [30], 
suggesting that elevated MMP12 expression may contribute to the fibrotic phenotype in 
the lungs and skin of floxed Fli1 CAG Cre mice.   
Few Fli1flox/flox CAG Cre mice had increased gene expression of TGFβ isoform, 
major contributors to SSc fibrosis, in the skin and lung [16-18]. Gene expression of α-
SMA was increased in both the lungs and skin after 4 weeks, but not 8 weeks, suggesting 
the presence of activated fibroblasts due to the loss of Fli1 and possible increase of TGFβ 
[16] in early stages.  The 50% of mice with this gene profile developed fibrosis in the 
skin and the lungs.  The gene expression of TGFβ isoforms is not striking and may need 
to be evaluated before the onset of fibrosis in the skin.  The protein level of TGFβ 
isoforms and collagens was not evaluated and give more insight into these mechanisms.  
The loss of the adipose tissue layer in the skin of experimental mice is consistent with 
adipose tissue involvement in the development of fibrotic lesions in SSc [31].  After 5 
months of Fli1 deletion, all floxed Fli1 mice expressing CAG Cre exhibited hair loss and 
pigmentation incontinence.  In SSc, hair loss is associated with vessel rarefaction [2]; 
counting the vessels in the affected skin of experimental mice may be promising.      
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There was no evidence if heart involvement after 4 weeks in these mice, however 
myocardial damage is typically secondary to pulmonary hypertension and kidney 
pathology [32].  Several mice died within a week of the last tamoxifen injection, 
indicating that the global loss of Fli1 has the potential to develop a fatal phenotype. The 
cause of death could not be determined, but two mice had enlarged necrotic kidneys.  
Further experiments utilizing these mice would focus on evaluating the effects of Fli1 
deletion in the liver and kidney, investigating gene expression in the skin earlier than 4 
weeks after Fli1 deletion, and further characterizing the phenotype in the lungs.  
The number of mice used for experiments was limited, and with the heterogeneity 
within groups, we were only able to observe trends in the lungs and skin.  Perhaps by 
increasing the number of mice per group and performing more experiments the variation 
seen between wild-type and CAG Cre mice may approach significance.  In our 
experiments, the CAG Cre transgene was active in 4-6 weeks old mice. Beginning 
tamoxifen injections in younger mice, or in pregnant dames may cause mice to develop a 
more profound and sustained phenotype.  Overall, these mice do not spontaneously 
develop the triad of SSc clinical manifestations as expected.  Genetic predisposition may 
only be enough to produce a strong vascular phenotype, while a secondary injury may be 
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